Ameriprise Financial Inc. Boosts Stock Holdings in Certara, Inc. (NASDAQ:CERT)

Ameriprise Financial Inc. raised its holdings in Certara, Inc. (NASDAQ:CERT - Free Report) by 864.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,779,655 shares of the company's stock after acquiring an additional 3,387,590 shares during the period. Ameriprise Financial Inc. owned about 2.35% of Certara worth $40,253,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CERT. ArrowMark Colorado Holdings LLC boosted its position in shares of Certara by 164.2% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company's stock worth $66,171,000 after buying an additional 3,861,674 shares during the period. Brown Brothers Harriman & Co. boosted its position in shares of Certara by 63.8% during the fourth quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company's stock worth $40,668,000 after buying an additional 1,487,998 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Certara by 169.0% during the fourth quarter. Bank of New York Mellon Corp now owns 1,995,071 shares of the company's stock worth $21,248,000 after buying an additional 1,253,385 shares during the period. ExodusPoint Capital Management LP acquired a new position in shares of Certara during the fourth quarter worth about $11,542,000. Finally, Teacher Retirement System of Texas raised its holdings in Certara by 13.9% during the fourth quarter. Teacher Retirement System of Texas now owns 4,557,951 shares of the company's stock worth $48,542,000 after acquiring an additional 557,348 shares in the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently issued reports on CERT shares. KeyCorp upped their target price on Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, April 16th. JMP Securities restated a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. TD Cowen began coverage on Certara in a research note on Thursday, February 27th. They issued a "buy" rating and a $16.00 price objective on the stock. Barclays upgraded Certara from an "equal weight" rating to an "overweight" rating and upped their price objective for the company from $11.00 to $14.00 in a research note on Thursday, May 8th. Finally, William Blair restated a "market perform" rating on shares of Certara in a research note on Thursday, February 27th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, Certara has an average rating of "Moderate Buy" and a consensus target price of $15.67.

Certara Trading Up 1.1%

CERT traded up $0.13 during midday trading on Friday, hitting $11.75. 230,415 shares of the company were exchanged, compared to its average volume of 1,302,487. The firm's 50 day moving average price is $11.70 and its 200-day moving average price is $11.71. Certara, Inc. has a 1-year low of $8.64 and a 1-year high of $17.76. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $1.91 billion, a P/E ratio of -58.58, a P/E/G ratio of 9.29 and a beta of 1.57.

Certara (NASDAQ:CERT - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.10 by $0.04. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The business had revenue of $106.00 million for the quarter, compared to the consensus estimate of $104.44 million. During the same quarter in the prior year, the business earned $0.10 earnings per share. Certara's revenue for the quarter was up 9.7% on a year-over-year basis. As a group, equities analysts forecast that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.